Trifluridine/tipiracil with or without bevacizumab in microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: A retrospective observational study

Hiroko Hasegawa, Rin Inamoto, Keiji Sugiyama, Naoki Izawa, Seiichiro Mitani, Takeshi Kawakami, Satoshi Yuki, Hidekazu Hirano, Saori Mishima, Tetsutaro Hamano, Toshiki Masuishi, Department of Gastroenterology and Hepatology, NHO Osaka National Hospital, Department of Gastroenterology, Saitama Cancer Center, Department of Medical Oncology, NHO Nagoya Medical Center, Department of Clinical Oncology, Marianna University School of Medicine, Department of Medical Oncology, Kindai University Faculty of Medicine, Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Department of Gastroenterology and Hepatology, Hokkaido University Hospital, Department of Cancer Genomics and Precision Medicine, Hirosaki University Graduate School of Medicine, Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Statistics Co, Department of Clinical Oncology, Aichi Cancer Center Hospital

Therapeutic Advances in Medical Oncology

Published online on August 06, 2026

Abstract

Therapeutic Advances in Medical Oncology, Volume 18, January-December 2026.
BackgroundPatients with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC) have been reported to exhibit resistance to various cytotoxic agents, including fluorouracil. A preclinical study showed ...